CDSCO Licensing in India 2026 – Apply Online

The pharmaceutical industry in India operates under a detailed regulatory framework designed to ensure that medicines are safe, effective, and meet required quality standards. The Central Drugs Standard Control Organisation (CDSCO) plays a key role in regulating drugs and coordinating important regulatory activities across India, working alongside State Licensing Authorities depending on the type of approval involved. This is especially relevant in 2026, since CDSCO recently replaced the traditional test license requirement with a faster "prior intimation" system for most low-risk drug development activities, while high-risk drugs still need a test license, now reviewed in 45 days instead of 90.

If your business is involved in drug manufacturing, importing, new drug development, clinical trials, or pharmaceutical distribution, understanding the applicable licensing requirements is essential for legal compliance and smooth market entry. This guide explains the CDSCO licensing process in India, major types of approvals, required documents, the SUGAM and NSWS portal process, applicable authorities, fees, timelines, and these important regulatory updates for 2026.

What Is CDSCO?

The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory authority for drugs, medical devices, and cosmetics under the Directorate General of Health Services, Ministry of Health & Family Welfare.

CDSCO performs important regulatory functions under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and other applicable regulations.

Its responsibilities include:

• Regulation of drug imports
• Approval of new drugs
• Regulation of clinical trials
• Granting certain drug-related licences and permissions
• Registration of foreign drug manufacturers for applicable imports
• Monitoring drug safety and quality
• Coordination with State Licensing Authorities
• Regulatory oversight of specified categories of drugs

For drug imports, CDSCO states that applications for Registration Certificates and Import Licences are processed under the applicable provisions of the Drugs and Cosmetics Rules through the SUGAM online system.

Why Is CDSCO Licensing Important?

Obtaining the correct regulatory approval is important before carrying out regulated pharmaceutical activities in India.

Depending on the product and business activity, the applicable approval or licence may be required for:

• Importing drugs into India
• Manufacturing drugs
• Conducting clinical trials
• Developing or marketing certain new drugs
• Testing specified drugs
• Distributing or selling drugs under the applicable State or central licensing framework

Proper licensing helps businesses:

• Meet regulatory requirements
• Reduce the risk of application rejection
• Support legal market entry
• Demonstrate compliance to business partners
• Maintain product quality and safety
• Avoid regulatory complications and enforcement action

It is important to identify the correct licence before applying, because CDSCO and State Licensing Authorities have different regulatory responsibilities.

Who Needs CDSCO Licensing or Approval?

CDSCO-related approval or licensing requirements may apply to:

• Pharmaceutical manufacturers
• Drug importers
• Foreign drug manufacturers
• Indian authorised agents of foreign manufacturers
• Companies developing new drugs
• Clinical research organisations (CROs)
• Clinical trial sponsors
• Pharmaceutical companies involved in regulated products
• Businesses involved in testing specified drugs

The exact requirement depends on the type of drug, intended activity, applicant, manufacturing site, and applicable regulatory category.

Key CDSCO Licences and Approvals

There is no single licence called a "CDSCO licence" that applies to every pharmaceutical business. Different activities require different permissions.

For drug imports, CDSCO's Import & Registration division identifies Form 41 as the Registration Certificate and Form 10/10A as applicable Import Licences for specified bulk drugs and finished formulations.

CDSCO vs State Licensing Authority

One of the most important things to understand is the difference between CDSCO and the State Licensing Authority (SLA).

CDSCO

CDSCO handles important central regulatory functions such as:

• Import regulation
• New drug-related approvals
• Clinical trial permissions
• Regulation of specified categories of drugs
• Registration of foreign manufacturers for applicable imports
• Coordination and oversight of central regulatory functions

State Licensing Authority

State authorities are involved in licensing and regulating activities such as applicable:

• Drug manufacturing
• Sale
• Distribution
• Wholesale activities

Therefore, a pharmaceutical company should not assume that every drug-related licence is issued directly by CDSCO.

How Do CDSCO and State Authorities Work Together?

The applicable authority depends on the activity and product.

For example:

Drug import → CDSCO

Domestic drug manufacturing → applicable State Licensing Authority and, where required, CDSCO involvement

New drug/clinical trial → CDSCO-related approval framework

The correct regulatory route should be determined before submitting an application.

CDSCO Licensing Process in India

The CDSCO licensing process depends on the type of drug, product, and approval required. The general process includes:

Step 1: Identify the Required Licence

Choose the applicable approval, such as Import Licence, Registration Certificate, Manufacturing Licence, New Drug Approval, Clinical Trial Permission, or Test Licence.

Step 2: Check Product Eligibility

Review the drug category, composition, intended use, manufacturing site, country of origin, labelling, and applicable regulatory requirements.

Step 3: Prepare Documents

Prepare the required application forms, product details, manufacturing documents, GMP certificates, stability data, labelling, Free Sale Certificate, and authorisation documents, as applicable.

Step 4: Submit Through SUGAM

Submit the applicable CDSCO application online through the SUGAM portal with the required documents and fees.

Step 5: Regulatory Review

CDSCO reviews the application and may raise queries, request additional documents, or seek clarification.

Step 6: Inspection, If Required

For applicable applications, CDSCO or the concerned authority may inspect the manufacturing facility, quality systems, documentation, and GMP compliance.

Step 7: Approval or Licence

Once all requirements are satisfied, the relevant CDSCO approval, certificate, or licence is issued. The timeline varies by licence type, product category, documentation, and regulatory review.

Documents Required for CDSCO Licensing

The documents required for CDSCO licensing depend on the type of application, product, and business activity. Common requirements include:

Note: The exact document list varies depending on the CDSCO licence, drug category, product type, applicant, and regulatory pathway. Applicants should verify the latest CDSCO requirements before submission.

CDSCO Licensing Timeline

The approval timeline varies depending on the type of application.

Factors that can affect the timeline include:

• Completeness of the application
• Product classification
• Regulatory pathway
• Number of products
• Technical documentation
• Regulatory queries
• Site inspection
• Applicant's response time
• Additional information requested by CDSCO

For this reason, businesses should avoid treating a general timeline such as "1 to 6 months" as a guaranteed approval period.

A complete and properly prepared application can help reduce avoidable delays.

SUGAM Portal for CDSCO Applications

The SUGAM portal is an important online platform used for submitting and tracking various CDSCO regulatory applications.

Depending on the application type, applicants can use the system for:

• Online application submission
• Document uploading
• Application tracking
• Regulatory communication
• Query responses
• Status monitoring

CDSCO continues to use SUGAM for regulatory submissions. For example, its 2026 public notices include provisions for submitting Periodic Safety Update Reports for new drugs through SUGAM and other application-related processes.

Important CDSCO Regulatory Updates in 2026

CDSCO continues to update India's pharmaceutical regulatory framework during 2026.

Some notable developments listed on CDSCO's official notifications include:

• Changes concerning Schedule H1
• Amendments affecting certain drug licensing provisions
• Restrictions concerning specified drug products
• Changes related to drug testing fees
• Regulatory changes concerning Schedule H2
• Proposals concerning shelf-life requirements
• Measures concerning misleading, fake, or fabricated documents
• Changes and clarifications affecting drug regulatory procedures

For example, CDSCO published a July 2026 notification concerning debarment of applicants for submitting misleading, fake, or fabricated documents. It also issued a June 2026 notification concerning additional categories under Schedule H2.

CDSCO also published a June 2026 circular regarding implementation of the pharmacovigilance system under Schedule M and a March 2026 guidance document on dossier-based licensing of drugs for uniform product licensing.

Because pharmaceutical regulations can change frequently, applicants should verify the latest CDSCO notification, circular, rule, and applicable guidance before submitting an application.

Common Challenges in CDSCO Licensing

Pharmaceutical companies often face challenges during the licensing process.

1. Incorrect Licence Selection

Choosing the wrong application category can result in delays and additional regulatory queries.

2. Incomplete Documentation

Missing documents, inconsistent information, or outdated certificates can affect application processing.

3. Technical Dossier Issues

Product composition, stability data, manufacturing information, and quality documents must be prepared carefully.

4. Regulatory Queries

CDSCO may raise technical or documentary queries that require accurate and timely responses.

5. Changing Regulations

Drug regulations and regulatory procedures can change through new notifications and circulars.

6. Foreign Manufacturer Compliance

Foreign manufacturers may need an Indian authorised agent and specific registration documentation before importing applicable products.

Need Help With CDSCO Licensing?

Planning to manufacture, import, or launch pharmaceutical products in India?

Contact PSR Compliance for professional assistance with CDSCO licensing and regulatory approvals.

Call: +91 8796104190
Email: support@psrcompliance.com

Conclusion

CDSCO licensing is an important part of pharmaceutical regulatory compliance in India. However, the applicable approval depends on the nature of the product, business activity, manufacturing or import arrangement, and regulatory category.

Businesses may need different approvals for drug imports, manufacturing, clinical trials, new drugs, testing, registration, and distribution.

A successful application requires the correct regulatory pathway, accurate documentation, appropriate technical information, and timely responses to regulatory queries.

Since CDSCO regulations and procedures continue to evolve, applicants should always verify the latest requirements before filing.

For businesses that need professional assistance, PSR Compliance can help with licence selection, documentation, SUGAM submission, regulatory coordination, and post-approval support.

FAQs About CDSCO Licensing in India

Q1. What is CDSCO licensing?

CDSCO licensing refers to the applicable licences, registrations, permissions, and regulatory approvals required for specified pharmaceutical activities regulated by CDSCO and the applicable drug laws in India.

Q2. Who needs a CDSCO licence?

Depending on the activity, pharmaceutical manufacturers, drug importers, foreign manufacturers, clinical trial sponsors, and companies involved in specified new drugs or regulated pharmaceutical products may require CDSCO approval or licensing.

Q3. What is the SUGAM portal?

SUGAM is an online CDSCO platform used for submitting and managing various regulatory applications and related communications.

Q4. What documents are required for CDSCO licensing?

Documents vary according to the licence. Common requirements may include company documents, product information, manufacturing details, GMP documents, stability data, certificates, labelling information, and authorisation documents.

Q5. How long does CDSCO licensing take?

The timeline depends on the licence type, product category, documentation, regulatory queries, inspections, and other factors. There is no single guaranteed timeline for all CDSCO applications.

Q6. What is a CDSCO Registration Certificate?

For applicable imported drugs, CDSCO issues a Registration Certificate for eligible foreign manufacturers and products. Form 41 is identified by CDSCO for the Registration Certificate under the applicable Drugs Rules framework.

Q7. Is CDSCO responsible for all drug licences in India?

No. CDSCO and State Licensing Authorities have different regulatory responsibilities. Certain domestic manufacturing, sale, and distribution activities are regulated through State authorities, while CDSCO handles specified central regulatory functions.

Q8. How can I track my CDSCO application?

Applicable applications submitted through SUGAM can generally be tracked through the applicant's online account and application dashboard.

Q9. Can foreign pharmaceutical companies apply for CDSCO approval?

Yes. Foreign manufacturers can follow the applicable Indian regulatory pathway for importing drugs into India. Depending on the product and activity, registration and import requirements may apply, including the appointment of an authorised Indian representative/agent where required.

Q10. Can PSR Compliance help with CDSCO licensing?

Yes. PSR Compliance can assist businesses with CDSCO licence selection, documentation, application preparation, SUGAM submission, regulatory coordination, query responses, and compliance support.